The purpose of this study is to evaluate the safety, tolerability, drug levels, food effects and relative bioavailability of BMS-986365 in healthy male participants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
102
Specified dose on specified days
Specified dose on specified days
Local Institution - 0001
Lenexa, Kansas, United States
Maximum observed plasma concentration (Cmax)
Time frame: Up to Day 75
Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration [AUC(0-T)]
Time frame: Up to Day 75
Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]
Time frame: Up to Day 75
To assess the bioavailability of BMS-986365 experimental formulation relative to the reference formulation
Time frame: Up to Day 75
Incidence of adverse events (AE)
Time frame: Up to Day 75
Incidence of serious adverse events (SAE)
Time frame: Up to Day 75
Number of participants with physical examination abnormalities
Time frame: Up to Day 75
Number of participants with vital sign abnormalities
Time frame: Up to Day 75
Number of participants with clinical laboratory abnormalities
Time frame: Up to Day 75
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to Day 75
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.